Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
FLGT Form 4 activity by transaction type, last 90 days
Form 4 transaction type
Transactions
Shares
Total value
Open-market sale
4
5,932
$117K
Tax withholding / forfeiture
7
19,349
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
FLGT insider transactions (Form 4)
37
86 Form 4 filings on record, the earliest from Oct 29, 2024, newest first. Filing history page 1 of 3.
Footnote F1 (shares): The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S… Full note on SEC EDGAR
Footnote F1 (shares): The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S… Full note on SEC EDGAR
Footnote F1 (shares): The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S… Full note on SEC EDGAR
Footnote F2 (price): The shares were sold in multiple transactions at prices ranging from $19.60 to $19.74, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the… Full note on SEC EDGAR
Footnote F1 (shares): The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S… Full note on SEC EDGAR
Footnote F2 (price): The shares were sold in multiple transactions at prices ranging from $19.60 to $19.74, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the… Full note on SEC EDGAR
Footnote F1 (shares): The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S… Full note on SEC EDGAR
Footnote F1 (shares): The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S… Full note on SEC EDGAR
Footnote F1 (shares): The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S… Full note on SEC EDGAR
Footnote F2 (price): The shares were sold in multiple transactions at prices ranging from $19.83 to $20.00, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the… Full note on SEC EDGAR
Footnote F1 (shares): The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S… Full note on SEC EDGAR
Footnote F2 (price): The shares were sold in multiple transactions at prices ranging from $19.83 to $20.00, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the… Full note on SEC EDGAR
Footnote F1 (shares): The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG… Full note on SEC EDGAR
Footnote F1 (shares): The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG… Full note on SEC EDGAR
Footnote F1 (shares): The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG… Full note on SEC EDGAR
Footnote F1 (shares): The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S… Full note on SEC EDGAR
Footnote F2 (price): The shares were sold in multiple transactions at prices ranging from $17.63 to $18.10, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the… Full note on SEC EDGAR
Footnote F1 (shares): The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S… Full note on SEC EDGAR
Footnote F1 (shares): The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S… Full note on SEC EDGAR
Footnote F2 (price): The shares were sold in multiple transactions at prices ranging from $17.63 to $18.10, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the… Full note on SEC EDGAR
Footnote F1 (shares): The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S… Full note on SEC EDGAR
Footnote F1 (shares): The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S… Full note on SEC EDGAR
Footnote F2 (price): The shares were sold in multiple transactions at prices ranging from $17.39 to $17.76, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the… Full note on SEC EDGAR
Footnote F1 (shares): The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S… Full note on SEC EDGAR
Footnote F1 (shares): The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S… Full note on SEC EDGAR
Footnote F2 (price): The shares were sold in multiple transactions at prices ranging from $17.39 to $17.76, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the… Full note on SEC EDGAR
Footnote F1 (shares): The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S… Full note on SEC EDGAR
Footnote F1 (shares): Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after May 14, 2026, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36… Full note on SEC EDGAR
Footnote F1 (shares): Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after May 14, 2026, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36… Full note on SEC EDGAR
Footnote F1 (shares): Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after May 14, 2026, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36… Full note on SEC EDGAR
Footnote F1 (shares): The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG… Full note on SEC EDGAR
Footnote F1 (shares): The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG… Full note on SEC EDGAR
Footnote F1 (shares): The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG… Full note on SEC EDGAR
Footnote F5 (price, shares): Previously, on August 21, 2023, the Hsieh Trust entered into a prepaid variable forward agreement (the "2023 Agreement") with an unaffiliated bank (the "Bank"). The 2023 Agreement obligated the Hsieh Trust to deliver up to 750,000 shares of the issuer's common stock, $0.0001 par… Full note on SEC EDGAR
Footnote F6 (price): On March 9, 2026, the Hsieh Trust elected to cancel the 2023 Agreement with respect to all 750,000 shares. In connection with the cancellation, the Hsieh Trust paid an aggregate of $10,708,875 to the Bank. Following the payment and cancellation described above, the 750,000… Full note on SEC EDGAR
Footnote F1 (shares): The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S… Full note on SEC EDGAR
Footnote F2 (shares): The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S… Full note on SEC EDGAR
Footnote F3 (shares): The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S… Full note on SEC EDGAR
Footnote F1 (shares): The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S… Full note on SEC EDGAR
Footnote F2 (shares): The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, , which grant was originally reported on Form 4 filed with the U.S… Full note on SEC EDGAR
Footnote F3 (shares): The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S… Full note on SEC EDGAR
Footnote F1 (shares): The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S… Full note on SEC EDGAR
Footnote F2 (shares): The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S… Full note on SEC EDGAR
Footnote F3 (shares): The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S… Full note on SEC EDGAR
An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
Fulgent Genetics, Inc. (FLGT) had 11 insider filings in the last 90 days, with the most recent on 2026-09-03. The full record for FLGT runs to 86 Form 4 filings, the earliest from 2024-10-29. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying FLGT stock?
No insider purchases of FLGT were filed in the last 90 days.
How many insiders are selling FLGT stock?
4 insider sales of FLGT were filed in the last 90 days, totaling $117K.
Where can I see FLGT SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects FLGT Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Michael Nohaile
Regina E. Groves
